Who is sponsoring NCT06875973?

NCT06875973 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT06875973?

Interventions in NCT06875973: Pelacarsen (TQJ230).

What condition does NCT06875973 study?

NCT06875973 studies Atherosclerotic Cardiovascular Disease.

Is NCT06875973 still recruiting?

NCT06875973 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT06875973

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pelacarsen Roll-over Extension Program

Recruiting now Phase 3 Last updated 15 April 2026

What this trial tests

Phase 3 trial testing Pelacarsen (TQJ230) in Atherosclerotic Cardiovascular Disease in 599 participants. Currently enrolling.

Timeline

19 May 2025

Primary endpoint
8 December 2030

8 December 2030

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	599
Start date	19 May 2025
Primary completion	8 December 2030
Estimated completion	8 December 2030
Sites	97 locations across Puerto Rico, United States

Drugs / interventions tested

Pelacarsen (TQJ230) — full drug profile →

Conditions studied

Atherosclerotic Cardiovascular Disease — all drugs for Atherosclerotic Cardiovascular Disease →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Atherosclerotic Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pelacarsen (TQJ230)

Trials testing the same drug.

NCT07517263 — An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit · Phase 3 · recruiting
NCT04993664 — Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA) · NA · withdrawn

Other recruiting trials for Atherosclerotic Cardiovascular Disease

Currently open trials in the same condition.

NCT07034690 — Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dy · Phase 4 · recruiting
NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
NCT06962488 — Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure · NA · recruiting
NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06875973 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing